CD24 and neoplasm: Thirteen percent (30/240) of the tumors were positive for more than one of the CD44+/CD24-, CD44-/CD24+ and CD44+/CD24+ phenotypes, with 5% (11/240) displaying tumor cells of all three phenotypes.